Liver Outcome in Renal Transplant Recipients Who Acquired Hepatitis C Infection From an Infected Graft : Study Based on Liver Biopsy Findings
Copyright © 2022 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc..
Long-term liver outcome in hepatitis C virus (HCV)-negative kidney recipients who acquired HCV infection from viremic donors is of intense interest in the transplant community. We evaluated the incidence of fibrosis in liver biopsy specimens of recipients who were transplanted with HCV-infected grafts.
Methods: Patients were evaluated in the hepatology clinic, and 29 patients agreed to undergo liver biopsy. The liver histology was scored by the meta-analysis of histological data in viral hepatitis scoring system and was assessed by hepatopathologists. The fibrosis score was compared between patients who initiated direct-acting antiviral (DAA) within 6 wk (n = 6) and after 6 wk (n = 29).
Results: Eighty-nine aviremic patients were transplanted with HCV-infected grafts between March 2018 and October 2019. All patients developed HCV infection and were treated with DAA treatment after kidney transplantation (median, 70 d; interquartile range, 55-85 d). All patients (n = 89) achieved sustained virologic response with DAA. The median follow-up time from kidney transplant to liver biopsy was 28 mo (interquartile range, 26-30 mo). Twenty-five patients (86%) had F0, and 4 patients (14%) had F1 fibrosis. No patient had advanced fibrosis (F3-F4). Grade 1 inflammation was present in 6 (21%) patients, whereas 26 (90%) patients had iron accumulation in the hepatocytes and reticuloendothelial cells. There was no difference in the fibrosis score between patients who received treatment within 6 wk versus after 6 wk (P = 0.55).
Conclusions: Kidney transplantation of HCV-infected graft to HCV-negative recipients is safe and has no long-term liver-related complications with successful eradication of HCV. In our cohort, delayed treatment did not affect sustained virologic response or liver histology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Transplantation direct - 8(2022), 6 vom: 16. Juni, Seite e1342 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kothadia, Jiten P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 16.07.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1097/TXD.0000000000001342 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341735779 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341735779 | ||
| 003 | DE-627 | ||
| 005 | 20231226012446.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/TXD.0000000000001342 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1139.xml |
| 035 | |a (DE-627)NLM341735779 | ||
| 035 | |a (NLM)35651584 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kothadia, Jiten P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Liver Outcome in Renal Transplant Recipients Who Acquired Hepatitis C Infection From an Infected Graft |b Study Based on Liver Biopsy Findings |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. | ||
| 520 | |a Long-term liver outcome in hepatitis C virus (HCV)-negative kidney recipients who acquired HCV infection from viremic donors is of intense interest in the transplant community. We evaluated the incidence of fibrosis in liver biopsy specimens of recipients who were transplanted with HCV-infected grafts | ||
| 520 | |a Methods: Patients were evaluated in the hepatology clinic, and 29 patients agreed to undergo liver biopsy. The liver histology was scored by the meta-analysis of histological data in viral hepatitis scoring system and was assessed by hepatopathologists. The fibrosis score was compared between patients who initiated direct-acting antiviral (DAA) within 6 wk (n = 6) and after 6 wk (n = 29) | ||
| 520 | |a Results: Eighty-nine aviremic patients were transplanted with HCV-infected grafts between March 2018 and October 2019. All patients developed HCV infection and were treated with DAA treatment after kidney transplantation (median, 70 d; interquartile range, 55-85 d). All patients (n = 89) achieved sustained virologic response with DAA. The median follow-up time from kidney transplant to liver biopsy was 28 mo (interquartile range, 26-30 mo). Twenty-five patients (86%) had F0, and 4 patients (14%) had F1 fibrosis. No patient had advanced fibrosis (F3-F4). Grade 1 inflammation was present in 6 (21%) patients, whereas 26 (90%) patients had iron accumulation in the hepatocytes and reticuloendothelial cells. There was no difference in the fibrosis score between patients who received treatment within 6 wk versus after 6 wk (P = 0.55) | ||
| 520 | |a Conclusions: Kidney transplantation of HCV-infected graft to HCV-negative recipients is safe and has no long-term liver-related complications with successful eradication of HCV. In our cohort, delayed treatment did not affect sustained virologic response or liver histology | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Bhalla, Anshul |e verfasserin |4 aut | |
| 700 | 1 | |a Molnar, Miklos Z |e verfasserin |4 aut | |
| 700 | 1 | |a Mohan, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a Balaraman, Vasanthi |e verfasserin |4 aut | |
| 700 | 1 | |a Talwar, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Helmick, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Eymard, Corey |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Richa |e verfasserin |4 aut | |
| 700 | 1 | |a Faust, Thomas W |e verfasserin |4 aut | |
| 700 | 1 | |a Vanatta, Jason M |e verfasserin |4 aut | |
| 700 | 1 | |a Eason, James D |e verfasserin |4 aut | |
| 700 | 1 | |a Nair, Satheesh P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation direct |d 2015 |g 8(2022), 6 vom: 16. Juni, Seite e1342 |w (DE-627)NLM249149893 |x 2373-8731 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2022 |g number:6 |g day:16 |g month:06 |g pages:e1342 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/TXD.0000000000001342 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2022 |e 6 |b 16 |c 06 |h e1342 | ||